HB 301
Alternative Names: HB-301Latest Information Update: 25 Jun 2024
At a glance
- Originator Hookipa Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 12 Jun 2024 Hookipa Pharma terminates a phase I/II trial in Prostate cancer (Metastatic disease) in USA (IV), for non-safety related reasons (NCT05553639)
- 03 Feb 2023 Phase-I/II clinical trials in Prostate cancer (Metastatic disease) in USA (IV) (NCT05553639)
- 23 Sep 2022 Hookipa Biotech plans a phase I/II trial for Prostate cancer (Metastatic) in US (IV) (NCT05553639)